Dissemination risk index based on plasminogen activator system components in primary breast cancer

Journal of Clinical Oncology

Volumn 17, Issue 10, 1999, Pages 3048-3057

  Bouchet, Cécile ^a   Hacène, Kamel ^a   Martin, Pierre Marie ^a   Becette, Véronique ^a   Tubiana Hulin, Michèle ^a   Lasry, Serge ^a   Oglobine, Jean ^a   Spyratos, Frédérique ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; UROKINASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER RISK; CANCER SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; RISK ASSESSMENT;

EID: 0344549142     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.10.3048     Document Type: Article

References (54)

1. Fentiman IS, Epstein R, Barr L: Is routine axillary nodal dissection necessary in the treatment of breast cancer? Eur J Cancer 32A: 1460-1463, 1996
2. Singletary SE: Management of the axilla in early-stage breast cancer. ASCO Educational Book, Spring: 132-141, 1998
3. Ravdin PM, De Laurentis M, Vendely T, et al: Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators. J Natl Cancer Inst 86:1771-1775, 1994
4. Dhingra K, Hortobagyi GN: Critical evaluation of prognostic factors. Semin Oncol 23:436-445, 1996 (suppl 4)
5. Andreasen PA, Kjoller L, Christensen L, et al: The urokinase-type plasminogen activator system in cancer metastasis. Int J Cancer 72:1-22, 1997
6. Duffy MJ, O'Grady P, Devaney D, et al: Urokinase-plasminogen activator, a marker for aggressive breast carcinomas: Preliminary report. Cancer 62:531-533, 1988
7. Janicke F, Schmitt M, Hafter R, et al: Urokinase-type plasminogen activator (uPA) antigen, is a predictor of early relapse in breast cancer. Fibrinolysis 4:69-78, 1990
8. Foekens JA, Schmitt M, van Putten WL, et al: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52:6101-6105, 1992
9. Spyratos F, Martin PM, Hacene K, et al: Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 84:1266-1272, 1992
10. Grondahl-Hansen J, Christensen IJ, Rosenquist C, et al: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53:2513-2521, 1993
11. Bouchet C, Spyratos F, Martin PM, et al: Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 69:398-405, 1994
12. Duggan C, Maguire T, McDermott E, et al: Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 61:597-600, 199
13. Janicke F, Schmitt M, Pache L, et al: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24:195-208, 1993
14. Foekens JA, Schmitt M, van Putten WL, et al: Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12:1648-1658, 1994
15. Knoop A, Andreasen PA, Andersen JA, et al: Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 77:932-940, 1998
16. Sumiyoshi K, Serizawa K, Urano T, et al: Plasminogen activator system in human breast cancer. Int J Cancer 50:345-348, 1992
17. Foekens JA, Buessecker F, Peters HA, et al: Plasminogen activator inhibitor-2: Prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 55:1423-1427, 1995
18. Kruithof EKO Baker MS, Bunn C: Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 11:4007-4024, 1995
19. Duggan C, Kennedy S, Kramer MD, et al: Plasminogen activator inhibitor type 2 in breast cancer. Br J Cancer 76:622-627, 1997
20. Foucre D, Bouchet C, Hacene K, et al: Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours. Br J Cancer 64:926-932, 1991
21. Bouchet C, Hacène K, Spyratos F, et al: Evaluation de a valeur pronostique d'un index d'invasivité (uPA X PAI-1)/PAI-2 dans le cancer du sein. Bull Cancer 81:517-524, 1994
22. Romain S, Spyratos F, Laine-Bidron C, et al: Comparative study of four extraction procedures for urokinase type plasminogen activator and plasminogen activator inhibitor-1 in breast cancer tissues. Eur J Clin Chem Clin Biochem 33:603-608, 1995
23. Bouchet-Bernet C, Spyratos F, Andrieu C, et al: Influence of the extraction procedure on plasminogen activator inhibitor-2 (PAI-2) and urokinase receptor (uPAR) assays in breast cancer tissues. Breast Cancer Res Treat 41:141-146, 1996
24. Bouchet C, Spyratos F, Hacene K, et al: Prognostic value of urokinase plasminogen activator in primary breast carcinoma Comparison of two immunoassay methods. Br J Cancer 77:1495-150, 1998
25. Bloom HJ, Richardson WW: Histological grading and prognosis in breast cancer: A study of 1,409 cases of which 359 have been followed for 15 years. Br J Cancer 11:359-377, 1957
26. Le Doussal V, Tubiana-Hulin M, Hacene K, et al. Nuclear characteristics as indicators of prognosis in node negative breast cancer patients. Breast Cancer Res Treat 14:207-216, 1989
27. EORTC Breast Cancer Co-Operative Group: Revision of the standards for the assessment of hormone receptors in human breast cancer: Report of the second EORTC Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute. Eur J Cancer 16:1513-1515, 1980
28. Wiechelman K, Braun R, Fitzpatrick J: Investigation of the bicinchoninic acid protein assay: Identification of the groups responsible for color formation. Anal Biochem 193:265-275, 1988
29. Kaplan EL, Meier P: Non-parametric estimation from incomplete observation. J Am Stat Assoc 53:457-481. 1958
30. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 35:1-39, 1977
31. Gower JC: Fisher's optimal scores and multiple correspondence analysis. Biometrics 4:947-961, 1990
32. Greenacre MJ: Theory and applications of correspondence analysis. London, England, London Academic Press, 1984
33. Harman HH: Modern factor analysis. Chicago, Illinois, The University of Chicago Press, 1967
34. Tubiana-Hulin M, Hacene K, Martin PM, et al: Prognostic factor clustering in breast cancer: Biology or Chronology? Eur J Cancer 31:282-283, 1995
35. Cox DR: Regression models and life-tables. J R Stat Soc (B) 34:187-220, 1972
36. Mignatti P, Robbins E, Rifkin DB: Tumor invasion through the human amniotic membrane: Requirement for a proteinase cascade. Cell 47:487-498, 1986
37. van Mourik JA, Lawrence DA, Loskutoff DJ: Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem 259:14914-14921, 1984
38. Bianchi E, Cohen RL, Dai A, et al: Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer. Int J Cancer 60:597-603, 1995
39. Christensen L, Wiborg SA, Heegaard CW, et al: Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas. Int J Cancer 66:441-452, 1996
40. Liu G, Shuman MA, Cohen RL: Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer 60:501-506, 1995
41. Bajou K, Noel A, Gerard RD, et al: Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 4:923-928, 1998
42. Wang N, Planus E, Pouchelet M, et al: Urokinase receptor mediates mechanical force transfer across the cell surface. Am J Physiol 268:C1062-C1066, 1995
43. Stefansson S, Lawrence DA: The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 383:441-443, 1996
44. Wei Y, Waltz DA, Rao N, et al: Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269:32380-32388, 1994
45. Kanse SM, Kost C, Wilhelm OG, et al: The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 244:344-353, 1996
46. Deng G, Curriden SA, Wang S, et al: Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 134:1563-1571, 1996
47. Kirchheimer JC, Nong YH, Remold HG: IFN-gamma, tumor necrosis factor-alpha, and urokinase regulate the expression of urokinase receptors on human monocytes. J Immunol 141:4229-4234, 1988
48. Schlechte JW, Boyd DD: Insensitivity of laminin degradation directed by receptor bound urokinase to PAI-1 in cultured colon cancer. Cancer Commun 2:261-269, 1990
49. Hollas W, Blasi F, Boyd D: Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res 51:3690-3695, 1991
50. Evans DM, Lin PL: Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor. Am Surg 61:692-696, 1995
51. Mueller BM, Yu YB, Laug WE: Overexpression of plasminogen activator inhibitor 2 in human melanoma cell inhibits spontaneous metastasis in scid/scid mice. Proc Natl Acad Sci U S A 92:205-209, 1995
52. Saxne T, Lecander I, Geborek P: Plasminogen activators and plasminogen activator inhibitors in synovia, fluid: Difference between inflammatory joint disorders and osteoarthritis. J Rheumatol 20:91-96, 1993
53. Dickinson JL, Bates EJ, Ferrante A, et al: Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis: Evidence for an alternate biological function. J Biol Chem 270:27894-27904, 1995
54. Janicke F, Pache L, Schmitt M, et al: Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 54:2527-2530, 1994